Key Information

NaMuscla: 1st licensed antimyotonic proven to control symptomatic myotonia.1-2

Long-term relief from myotonia irrespective of channelopathy - a retrospective chart review.3

NaMuscla: Well tolerated, and suitable for long-term use.3

NaMuscla: A daily, long-term treatment for relief from myotonia.1


Reporting of side effects

Product details

Contact Us

© Lupin Healthcare Limited 2021   LUP-CORP-005   Last Updated: December 2020

scroll to top